Arcturus Therapeutics will present a scientific poster on its ARCT-810 mRNA therapy at a symposium in Helsinki. The presentation details the therapy's impact on dietary intake and biochemical data in patients with Ornithine Transcarbamylase (OTC) Deficiency.
The company expects to release additional data and a comprehensive regulatory plan for the ARCT-810 program later this quarter.
Arcturus shares have surged over 60% in the past week. This momentum follows positive sector sentiment from Moderna and Merck’s mRNA cancer vaccine results. Arcturus also recently regained global rights to its COVID vaccine.